Telzir 700 mg/ 50 mg TABLETS. ORAL SUSPENSION
PDF Leaflet Revision Date: 11 March 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of HIV in combination with other antiretroviral medicines.
Dosage (summary)
Adults: 1400 mg once daily or 700 mg twice daily with ritonavir.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy or breastfeeding due to lack of safety data.
Key Drug Interactions
- CYP3A4 inhibitors
- Rifampicin
- St John's Wort
- PDE5 inhibitors
Contraindications
- Severe hepatic impairment
- Hypersensitivity to components
- Concomitant use with ketoconazole
Common side effects
- Diarrhea
- Headache
- Rash
- Hypertriglyceridemia
Counselling Points
- Take with food for children
- Monitor for signs of hypersensitivity
- Regular viral load monitoring required
Serious warnings
- Risk of opportunistic infections
- Hypersensitivity reactions
- Increased bleeding in hemophiliacs
Important Disclaimer
The Telzir 700 mg/ 50 mg TABLETS. ORAL SUSPENSION professional information leaflet below is the property of Glaxosmithkline South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
